If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
2,004.00    74.00 (3.83%)
Bid:
2,011.00
Ask:
2,012.00
Spread: 1.00 (0.05%)
Market Cap: £80.27b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Block listing Interim Review

15 Nov 2022 16:00

RNS Number : 4282G
GSK PLC
15 November 2022
 

  BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 15 November 2022

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2022

To:

31 October 2022

Balance of unallotted securities under scheme(s) from previous return:

44,219

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

44,219

  

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2022 

To:

31 October 2022

Balance of unallotted securities under scheme(s) from previous return:

1,373,495

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

251,620

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,121,875

  

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRDELBFLFLXFBB
Date   Source Headline
11th Aug 20257:00 amRNSFDA to review gonorrhea indication for gepotidacin
11th Aug 20257:00 amRNSTransaction in Own Shares
8th Aug 20257:00 amRNSCureVac/BioNTech mRNA patent litigation settlement
8th Aug 20257:00 amRNSTransaction in Own Shares
7th Aug 20257:00 amRNSTransaction in Own Shares
6th Aug 20257:00 amRNSTransaction in Own Shares
5th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20253:00 pmRNSTotal Voting Rights
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
30th Jul 20257:05 amRNSTransaction in Own Shares
30th Jul 20257:00 amRNS2nd Quarter Results
29th Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 20257:00 amRNSGSK enters Hengrui Pharma collaboration agreements
28th Jul 20257:00 amRNSTransaction in Own Shares
25th Jul 20257:00 amRNSTransaction in Own Shares
24th Jul 20255:00 pmRNSBlenrep approved in the EU for multiple myeloma
24th Jul 20257:00 amRNSTransaction in Own Shares
23rd Jul 20255:00 pmRNSUS FDA review extended for Blenrep
23rd Jul 20257:00 amRNSTransaction in Own Shares
22nd Jul 20257:00 amRNSTransaction in Own Shares
21st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20253:30 pmRNSDirector/PDMR Shareholding
18th Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSBlenrep US ODAC outcome
17th Jul 20257:00 amRNSGSK’s Shingrix Fully Liquid FDA approval
17th Jul 20257:00 amRNSTransaction in Own Shares
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20253:30 pmRNSDirector/PDMR Shareholding
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20253:30 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSGSK submits Arexvy for adults 18-49 AIR to FDA
14th Jul 20257:00 amRNSTransaction in Own Shares
11th Jul 20257:00 amRNSTransaction in Own Shares
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20257:00 amRNSTransaction in Own Shares
7th Jul 20254:00 pmRNSGSK completes acquisition of efimosfermin for SLD
7th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 20257:00 amRNSTransaction in Own Shares
3rd Jul 20257:00 amRNSTransaction in Own Shares
2nd Jul 20257:00 amRNSTransaction in Own Shares
1st Jul 20253:00 pmRNSTotal Voting Rights
1st Jul 20257:00 amRNSTransaction in Own Shares
30th Jun 20257:00 amRNSTransaction in Own Shares
27th Jun 20257:00 amRNSTransaction in Own Shares
26th Jun 20257:00 amRNSTransaction in Own Shares
25th Jun 20257:00 amRNSTransaction in Own Shares
24th Jun 20253:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.